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ABSTRACT
OBJECTIVE: The objective of this systematic review is to determine whether or not topical 1%
pimecrolimus cream is an effective treatment for rosacea.
STUDY DESIGN: Review of three English language primary studies published between 2007
and 2008.
DATA SOURCES: Randomized, controlled, investigator-blind clinical trials comparing topical
1% pimecrolimus application to either placebo cream or an untreated portion of the face were
found using OVID, MEDLINE, and Cochrane Databases.
OUTCOMES MEASURED: Rosacea severity and improvement. Rosacea severity was assessed
using the Rosacea Severity Score, set forth by the National Rosacea Society Expert Committee,
which classifies the severity of erythema, papules, pustules, edema, and telangiectasia on a scale
of 0 (no symptoms) to 3 (severe symptoms). Subjective severity scores were assigned using a
visual analog scale (VAS) to assess rosacea severity on a scale of 0 (clear) to 5 (very severe).
Rosacea severity was also assessed using a Subjective Severity Assessment (0-100 scale) and an
investigators’ global assessment of erythema, papules, and total inflammatory lesions.
RESULTS: Dichotomous data from the Karabulut et al. study did not show the use of topical
1% pimecrolimus cream to result in statistically significant improvement in rosacea severity, as
measured by the Rosacea Severity Score, when compared to placebo cream. Dichotomous data
presented by Lee et al. did not show statistically significant improvement in rosacea severity, as
measured by investigators’ global assessment of erythema and papules. Dichotomous data from
Weissenbacher et al. did not show statistically significant improvement in severity of clinical
rosacea signs (erythema, papules, scaling, and pustules) as measured by the Rosacea Severity
Score and the Subjective Severity Score after use of topical 1% pimecrolimus cream.
CONCLUSIONS: Dichotomous data presented by Karabulut et al., Weissenbacher et al., and
Lee et al. did not show the application of topical 1% pimecrolimus cream to cause statistically
significant improvement in rosacea severity. Based on this finding, all three studies indicate that
topical 1% pimecrolimus cream is not more efficacious in improving rosacea severity when
compared to placebo cream or an untreated portion of the face.
KEY WORDS: Rosacea, Pimecrolimus, Elidel
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INTRODUCTION
Rosacea is a common, chronic inflammatory disease affecting the face that occurs
primarily between the ages of thirty and fifty. Rosacea has both a neurovascular presentation, as
evidenced by erythema, telangiectasia, and flushing, as well as an acneiform presentation,
manifested by the presence of papules and pustules. In addition to the neurovascular and
acneiform components, certain forms of rosacea have a glandular presentation involving
hyperplasia of the nasal soft tissue known as rhinophyma. Common sites of rosacea distribution
are on the cheeks, nose, and chin. Rosacea is characterized by periods of remissions and relapses
which are treated symptomatically, to varying degrees of success, with different topical and
systemic medications and therapies.5
In terms of clinical relevance to Physician Assistants in practice, rosacea is a prevalent
condition that is likely to be encountered by practitioners in almost all primary care settings. It is
estimated that fourteen million Americans have rosacea. While the number of primary care
office visits associated with rosacea each year has not be formally analyzed in the medical
literature, the chronic nature of rosacea, as well as the tendency for the condition to flare and
remit over an adult’s lifetime, is likely associated with recurrent patient visits. Long term
treatment for chronic rosacea flares can also be a costly endeavor for the patient. One study by
Thomas et al. found the financial cost of standard topical rosacea medications, systemic
antibiotics, isoretinoin, and topical immunomodulators to be significant, ranging from $60.90 per
success using metronidazole 1% gel once daily to $152.25 per success using azelaic acid 20%
cream twice daily. Furthermore, these cost estimations do not include the additional expense of
office visits to the dermatologist or other primary care provider. Laser treatment for rosacea is
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often considered to be a cosmetic procedure and is therefore not commonly covered by
insurance, resulting in notable out-of-pocket cost for the patient.6
The current standard of treatment for rosacea is topical 0.75% to 1% metronidazole
creams, lotions, and gels applied once daily. Topical 1% clindamycin, in the same vehicle
forms, can be used twice daily if metronidazole is not tolerated. In patients who only exhibit a
partial response to topical antibiotic treatment, sulfur-sodium sulfacetamide-containing topical
treatments may be used, as well as topical benzoyl peroxide for control of persistent pustular
presentations. When topical therapy proves inefficacious, systemic therapies such as tetracycline
250-500 mg orally twice daily on an empty stomach may be used. Cases that are refractory to
tetracycline may be aided by the use of oral minocycline or doxycycline 50-100 mg daily to
twice daily.5
It is known that patients with rosacea often report exacerbation of rosacea symptoms
with ingestion of spicy food, hot drinks, or alcohol, exposure to sunlight, exposure to extreme
heat or cold, exercise, and during emotional periods. These activities are thought to cause the
release of vasoactive mediators, resulting in vasodilation and the subsequent flushing associated
with rosacea. A concrete, definitive etiopathogenesis for rosacea remains unknown at the current
time, but pathophysiology research on the mechanics of rosacea suggests that immune or
inflammatory factors such as eicosanoids, nitric oxide, and proinflammatory cytokines may play
a pivotal role in rosacea symptomatology.2 Based on this pathophysiological research, it has
been hypothesized that anti-inflammatory and/or immunomodulating agents may be effective
methods of treating rosacea.
Pimecrolimus is a calcineurin inhibitor and ascomycin macrolactam derivative that has
immunomodulatory and anti-inflammatory effects. Commercially marketed under the name
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Elidel, pimecrolimus is administered in the form of a 1% concentration topical cream. Topical
1% pimecrolimus cream works by selecting target T-lymphocytes and mastocytes, and inhibiting
the production and release of inflammatory cytokines such as tumor necrosis factor-alpha,
interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, and IL-10.2 In addition, topical 1% pimecrolimus is
thought to function by blocking expression of chemomodulators that activate inflammatory Tcells in the body. Based on the known immunomodulating effects of pimecrolimus and the
suspected underlying inflammatory and immunological pathophysiology of rosacea, topical
pimecrolimus has been investigated as a potential treatment to reduce the incidence and severity
of rosacea symptoms.
OBJECTIVE
The objective of this systematic review is to determine whether or not, “Is topical 1%
pimecrolimus cream an effective treatment for rosacea?” A 2007 Cochrane Review of existing
medical literature found topical 1% pimecrolimus cream to be significantly more effective than
vehicle/placebo cream in the short term (<6 weeks) and long-term (>6 weeks) treatment of atopic
dermatitis.1 Although the pathophysiology of both rosacea and atopic dermatitis is thought to
involve inflammatory and immunologic responses in T-cells, a meta-analysis of the efficacy of
1% pimecrolimus on rosacea has not been performed to date.
METHODS
A detailed search was completed by the author, using the search engines MEDLINE,
OVID, and the Cochrane Database of Systematic Reviews. The key words, “Pimecrolimus,”
“Elidel,” and “Rosacea” were used in combination to search for English-language articles. All of
the resulting articles from the search were published in peer-reviewed journals between 1996 and
2010. The articles were selected based on importance of the outcomes to the patient (i.e. Patient
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Oriented Evidence that Matters, or POEMS). Studies that were included were those that were
randomized, controlled studies, published after 1996 focusing on a patient oriented outcome for
adults aged 18 or older. Excluded studies were those in which the subjects were under the age of
18 and/or articles that were published before 1996. Randomized control trials (RCTs) were
searched and selected based on the evidence that they focused on a patient population over 18
years of age that had been clinically diagnosed with rosacea, as well as the evidence that the
studies involved application of topical 1% pimecrolimus as the treatment intervention.
Furthermore, only those articles that compared topical 1% pimecrolimus to the use of placebo
cream or to the use of no cream at all were included in this review. Based on the aforementioned
criteria, three investigator-blind, randomized, placebo-controlled clinical trials were selected and
included in this review. Table 1 delineates the demographics of the studies included in this
review.
The study by Karabulut et al. reported statistics based on the Rosacea Severity Score,
Visual Analog Scale (VAS), and Total Rosacea Severity Score (i.e. sum of individual Rosacea
Severity Scores). The study by Lee et al. reported statistics based on a VAS assessment as well
as the investigators’ global assessment of erythema, papules, total inflammatory lesion count,
and proportion of affected areas after 1, 2, 4, and 8 weeks and at baseline visit. The study by
Weissenbacher et al. reported statistics based on the Rosacea Severity Score, a VAS Subjective
Severity Score, and a Dermatology Life Quality Index (DLQI). For this review, selected
dichotomous data from the Karabulut et al. and Weissenbacher et al. studies were interpreted into
numbers needed to treat (NNT), while selected dichotomous data reported in the Lee et al. study
were interpreted into numbers needed to harm (NNH).
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Table 1. Characteristics of Studies Included in Systematic Review of the Efficacy of 1%
Topical Pimecrolimus Cream Versus Placebo in the Treatment of Rosacea
Study
Type
# of Age
Inclusion
Exclusion Criteria
W/D Intervention
Pts
Criteria
Karabulut, RCT
25
23-60 Adult
No
N/A Split-face
2008
(Investigay.o.
rosacea
extrafacial/ocular
application
(1)
tor blind,
patients
lesions, pregnant or
of 1%
randomizw/
breastfeeding,
topical
ed placebo
bilateral
hypersensitivity to
pimecrolimcontrolled,
papulopu- Elidel, viral or
us cream
split-face
stular
malignant disease,
(Elidel) for
trial)
rosacea
severe ocular
4 weeks
lesions
rosacea or severe
flare-up reaction in
the past, previous
rosacea tx 4 weeks
prior entry of into
study
Lee, 2008 RCT
18
Mean At least 18 No severe skin
3
Use of 1%
(2)
(Investigaage
y.o.,
lesions requiring
pimecrolimtor blind,
43.9
diagnosed systemic tx other
us cream on
randomizy.o.
with
than antihistamine,
one half of
ed, split+/steroidacne vulgaris,
the subject’s
face trial)
15.9
induced
debilitating medical
face for 2
yrs.
rosacea,
disorders, use of
weeks
previous
HRT or oral
(2x/day)
hx of
corticosteroid,
followed by
topical
previous facial laser
6 weeks of
corticoste- tx or surgical
1%
roid use
procedures 4 weeks
pimecrolimfor >2
prior to study
us cream
weeks
enrollment,
application
pregnant and
on the
lactating women
whole face
(2x/day)
Weissenb- RCT
40
36-76 Pts with
Specific exclusion
N/A Daily
acher,
(Randomy.o.
papulopu- guidelines were not
application
2007
ized
stular
delineated in paper
of a 1%
(3)
vehiclerosacea
pimecrolimcontrolled,
us cream to
doublethe face B/L
blind trial)
for tx of
papulopustular rosacea
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OUTCOMES MEASURED
The primary outcomes measured in all three studies were rosacea severity and
improvement as quantified by the National Rosacea Society Expert Committee’s Rosacea
Severity Score system.8 The Rosacea Severity Score assesses the severity of four key rosacea
symptoms (i.e. erythema, papules, scaling, pustules) and rates them on a scale of 0 to 3, with 0
representing a complete absence of symptoms, 1 representing mild symptoms, 2 representing
moderate symptoms, and 3 representing severe symptoms. Karabulut et al. also examined Total
Rosacea Severity Score by analyzing the sum of various individual severity assessments.
All three studies involved Subjective Severity Assessment of rosacea using some form of
a Visual Analog Scale (VAS). Karabulut et al. performed a subjective severity assessment of
each subject’s rosacea severity using VAS on a 0 to 10 mm scale. The study by Lee et al. had
each subject conduct his/her own VAS assessment of the severity of his/her facial lesions and
pruritus on a 0 to 100 scale (where 0 is absence of symptoms and 100 is severe). Weissenbacher
et al. performed a subjective severity assessment using a VAS on a scale of 0 mm to 100 mm
(where 0 is “no skin changes” and 100 is “very severe skin changes”). Rosacea severity and
improvement were also measured via an assessment of erythema, papules, total inflammatory
lesion count, and proportion of affected areas after 1, 2, 4, and 8 weeks and at baseline visit via
Investigators’ Global Assessment of Severity.3
RESULTS
The results, as they pertain to the measured outcomes, were presented primarily as
dichotomous data in each of the three studies and analyzed as dichotomous data. While three
participants withdrew from the Lee et al. study, and one participant withdrew from the Karabulut
et al. study, the data from each study were presented as an intention to treat analysis.
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Karabulut et al. reported rates of rosacea severity improvement as 0.5416% and 0.125%
in the experimental and control group respectively. This difference was not statistically
significant as p-values were not provided for this data. The relative benefit increase (RBI) was
calculated to be 3.33%, while the absolute benefit increase (ABI) was calculated as 0.4166%.
Based on these calculations, the number needed to treat (NNT) for this study was 2.4 using
topical 1% pimecrolimus cream. This is clinically important in that, for every 2.4 patients
treated with 1% pimecrolimus cream, 1 more patient had improved rosacea as compared to the
control group (Table 2).
Weissenbacher et al. reported rates of rosacea severity improvement as 0.32% and 0.37%
in the experimental and control group respectively. This difference was not statistically
significant as p-values were not provided for this data. The relative benefit increase (RBI) was
calculated to be 0.135%, while the absolute benefit increase (ABI) was calculated to be -0.05%.
Based on these calculations, the number needed to treat (NNT) for this study was -20.0. This is
clinically significant in that, for every 20 patients treated with the 1% pimecrolimus cream, 1
patient fewer had improved rosacea compared to the control (Table 2).
Lee et al. reported rates of rosacea severity improvement as 0.2% and 0.0% in the
experimental and control group respectively. The difference was not statistically significant as
p-values were not provided for this data. The relative risk increase (RRI) was calculated to be
0.0%, while the absolute risk increase (ARI) was calculated to be 0.2%. Based on these
calculations, the number needed to harm (NNH) for this study was 5. This is clinically important
because for every 5 patients treated with 1% pimecrolimus cream, 1 more patient had worsened
rosacea symptoms as compared to the control group (Table 3). The study by Lee et al. was
unique in that it specifically analyzed the effect of 1% topical pimecrolimus on steroid-induced
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rosacea as opposed to idiopathic rosacea. It is also important to note that there were pieces of
continuous data discussed in the Lee et al. study (i.e. results of the investigator’s global
assessment of erythema and papules, lesion counts of papules and pustules, and percentage of
facial areas involved measured at 1, 2, 4, and 8 weeks from baseline) that may suggest a
significant therapeutic role for 1% pimecrolimus in the treatment of steroid-induced rosacea.
However, the aforementioned pieces of continuous data could not be converted to dichotomous
data for the purpose of this review and were therefore not included in the analysis.
Table 2. Efficacy of Topical 1% Pimecrolimus in Improvement of Rosacea - NNT
Study
Control
Experimental
Relative
Absolute
Number
Event Rate
Event Rate
Benefit
Benefit
Needed to
(CER)
(EER)
Increase
Increase
Treat (NNT)
(RBI)
(ABI)
Karabulut,
0.125%
0.5416%
3.33%
0.4166%
2.40
2008
Weissenbacher, 0.37%
0.32%
0.135%
-0.05%
-20.0*
2007
* This negative value for NNT indicates that for every 20 patients treated with the experimental
treatment (i.e. topical 1% pimecrolimus cream), 1 patient fewer had improved rosacea compared
to the control. P-values and 95% CI were not provided for the dichotomous data presented in
the studies.
Table 3. Efficacy of Topical 1% Pimecrolimus in Improvement of Rosacea - NNH
Study
Control Event Experimental Relative Risk Absolute Risk
Numbers
Rate (CER)
Event Rate
Increase
Increase
Needed to
(EER)
(RRI)
(ARI)
Harm (NNH)
Lee, 2008
0%
0.2%
0%
0.2%
5*
* P-values and 95% CI were not provided for the dichotomous data presented in the study.
In terms of adverse effects encountered by subjects in the studies included in this
analysis, Lee et al. reported that 20% of subjects (i.e. three of the fifteen subjects involved in the
study) experienced side-effects like burning or stinging at the site of pimecrolimus application or
hyperpigmentation of an initially inflamed area of skin prior to pimecrolimus application.
Notably, no patients participating in the Lee et al. study reported an exacerbation of their rosacea
signs after application of the pimecrolimus. Side effects associated with treatment in the
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Karabulut et al. study included mild and transient local irritation of the skin. Three patients in
this study complained of transient stinging/burning/itching of the skin lasting 5 to 10 minutes
after application of pimecrolimus during the first 5 to 7 days of the trial. Two patients
complained of lip dryness during the trial. One patient ultimately withdrew from the study at the
second week due to a “severe flare up reaction.”2 In the Weissenbacher et al. study, one patient
complained of facial skin tightness and another patient complained of pruritus.
DISCUSSION
Pimecrolimus is a topical calcineurin inhibitor and immunomodulator. Clinically
indicated for the treatment of atopic dermatitis by the U.S. Food and Drug Administration,
pimecrolimus acts by penetrating the inflamed epidermal layer of the skin and inhibits the
transcription and activation of proinflammatory cytokines including IL-2, IL-4, IL-10, and
interferon gamma. This ultimately prevents the immunologic activation of T-cells. Adverse
reactions to the drug include headache, burning at the site of application, and nasopharyngitis.
According to the U.S. Black Box warning, topical calcineurin inhibitors have been associated
with rare cases of skin malignancy and lymphoma, and should therefore be used only in shortterm and intermittent treatment regimens with application to limited surface areas. Further,
pimecrolimus is not recommended for use in children under the age of 2 years.
Contraindications for use of the drug include hypersensitivity to pimecrolimus or any other
components in its formulation.4
The studies chosen for analysis had several limitations. Each study assessed the
qualitative severity of rosacea via the National Rosacea Society Expert Committee guidelines.
However, due to the uncontrollable triggers of rosacea (i.e. stress, sunlight, menstruation, hot
environments), the therapeutic impacts of the pimecrolimus may have been altered, which in turn
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may have affected the rosacea severity of each patient and his/her Rosacea Severity Score. In
the study by Lee et al., subjects were given the opportunity to assess their own rosacea severity
via a visual analog scale. Based on the subjective nature of self-assessment, these visual analog
scale scores may not have been well-standardized or controlled. In the Lee et al. study, three
subjects experienced adverse effects (i.e. burning, stinging) and one patient complained of
postinflammatory hyperpigmentation, and three subjects dropped out early in the study for
reasons including noncompliance, loss of follow-up, and protocol violations. This change in
subject enrollment may have impacted the accuracy of the study outcomes. The study by
Weissenbacher et al. also utilized a placebo cream for the control group that may have had
emollient properties to reduce skin scaling and dryness. The therapeutic effects of this placebo
vehicle cream may have caused improvement in rosacea severity symptoms, thereby impacting
the significance of the rosacea severity improvement in the experimental group.
CONCLUSION
The studies reviewed demonstrate that the topical application of 1% pimecrolimus cream
is not an effective treatment for rosacea in that it is not shown to cause a statistically significant
improvement in the severity of rosacea. There were multiple methods used to assess rosacea
severity in each of the studies analyzed, including the Rosacea Severity Score set forth by the
National Rosacea Society Expert Committee, Visual Analog Scores with differing numerical
scales and means of assessment (i.e. self-assessment and investigator assessment), and an
investigator assessments of global rosacea severity. The use of such a variety of assessment
tools makes it difficult to do side-by-side comparisons of results (i.e. improvement in rosacea
severity) from multiple studies as rosacea severity is qualitatively and quantitatively analyzed by
differing parameters. Future studies evaluating the efficacy of pimecrolimus in reduction of
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rosacea symptoms should use one central method of assessment, such as the Rosacea Severity
Score set forth by the National Rosacea Society Expert Committee, to evaluate results. Future
investigations may be warranted in the investigation of the effects of 1% pimecrolimus cream on
steroid-induced rosacea as compared to the effects of 1% pimecrolimus cream on rosacea
occurring in non-steroid users. In addition, future tests may focus experimental methods on the
split-face method of experimental control, so as to evaluate the effects of pimecrolimus versus
placebo on the same face with the same baseline severity of rosacea symptoms.
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